Search - tctmd.com

Displaying 821 - 840 of 2956

Sort: Relevancy | Date

Presentation TCT 2017

Impact of Sex, Race, Socioeconomic Status, and Region/Country on Acute and Late PCI Outcomes

Presenter: Alice K. Jacobs, Spencer B. King III

October 31, 2017

Presentation TCT 2017

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Anson Cheung

October 31, 2017

Presentation TCT 2017

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

Presenter: Antonio Colombo, David E. Kandzari, Davide Capodanno

October 31, 2017

Presentation TCT 2017

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

Presenter: John K. Forrest

October 31, 2017

Presentation TCT 2017

Debate: Should CHIP Success Be Defined by Complete Revascularization? Con!

Presenter: Farouc Jaffer, Ajay J. Kirtane

October 31, 2017

Presentation TCT 2017

Intracoronary Pharmacology: Approach to Thrombus and the Prevention and Treatment of No Reflow

Presenter: David P. Faxon, Robert S. Schwartz, Raffaele Piccolo

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

Synthesis of Randomized Trial and Registry Data for Devices in Cardiogenic Shock: What Is the Evidence for Efficacy?

Presenter: Vladimir Dzavik, Navin K. Kapur, Nicolas M. Van Mieghem

October 31, 2017

Presentation TCT 2017

CMS Strategy and the Move to Value

Presenter: Peter L Duffy, Hadley Wilson, John A. Spertus

October 31, 2017

Presentation TCT 2017

Embolic Protection Devices For TAVR Procedures: Lessons Learned From SENTINEL and Other Experiences

Presenter: Martin B. Leon, Changfu Wu

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From the Euro-CTO Trial

Presenter: Barry D. Rutherford, Robert W. Yeh, Gerald S. Werner

October 31, 2017

Presentation TCT 2017

Trans-septal Puncture for LAA Closure Using Fluoroscopic Guidance

Presenter: Stefan C. Bertog, Apostolos Tzikas, Randall J. Lee

October 31, 2017

Presentation TCT 2017

Use of NCDR Registries to Evaluate Race and Gender Issues Related to Medications and Devices

Presenter: Alice K. Jacobs, Spencer B. King III, John C. Messenger

October 31, 2017

Presentation TCT 2017

Ukraine Presents to Egypt: Complications During a CTO PCI

Presenter: Mohammad Al-Mutairi, Ahmed Magdy, Maxim Sokolov

October 31, 2017

Presentation TCT 2017

SAPIEN 3 Procedural Pearls (Including Optimal Sizing Algorithms)

Presenter: Susheel K. Kodali

October 31, 2017

Presentation TCT 2017

NOBLE: Core Findings Revisited and New Data

Presenter: Antonio Colombo, David E. Kandzari, Evald H. Christiansen

October 31, 2017

Presentation TCT 2017

Debate: Should CHIP Success Be Defined by Complete Revascularization? Pro!

Presenter: Farouc Jaffer, Ajay J. Kirtane, William L. Lombardi

October 31, 2017

Presentation TCT 2017

Coronary Flow, Collateral Flow, and Fractional Flow Reserve in Culprit and Nonculprit Lesions in STEMI

Presenter: David P. Faxon, Robert S. Schwartz, Matthias Götberg

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Advertisement

Impact of Sex, Race, Socioeconomic Status, and Region/Country on Acute and Late PCI Outcomes

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

EVOLUT R TAVR Technology Review (Including EVOLUT 34mm and PRO) and Clinical Program Updates

Debate: Should CHIP Success Be Defined by Complete Revascularization? Con!

Intracoronary Pharmacology: Approach to Thrombus and the Prevention and Treatment of No Reflow

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Synthesis of Randomized Trial and Registry Data for Devices in Cardiogenic Shock: What Is the Evidence for Efficacy?

CMS Strategy and the Move to Value

Embolic Protection Devices For TAVR Procedures: Lessons Learned From SENTINEL and Other Experiences

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Outcomes and Clinical Implications From the Euro-CTO Trial

Trans-septal Puncture for LAA Closure Using Fluoroscopic Guidance

Use of NCDR Registries to Evaluate Race and Gender Issues Related to Medications and Devices

Ukraine Presents to Egypt: Complications During a CTO PCI

SAPIEN 3 Procedural Pearls (Including Optimal Sizing Algorithms)

NOBLE: Core Findings Revisited and New Data

Debate: Should CHIP Success Be Defined by Complete Revascularization? Pro!

Coronary Flow, Collateral Flow, and Fractional Flow Reserve in Culprit and Nonculprit Lesions in STEMI

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content